Androgen regulation of prostate cancer: where are we now?
about
Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinologySexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in VivoTestosterone and cardiovascular risk.Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.The significance of galectin-3 as a new basal cell marker in prostate cancer.Risks and benefits of late onset hypogonadism treatment: an expert opinion.Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.Quality of Life and Sexual Health in the Aging of PCa Survivors.Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.Benign prostatic hyperplasia: a new metabolic disease?Injectable testosterone undecanoate for the treatment of hypogonadism.Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.Aging and sexual health: getting to the problem.Endocrine control of benign prostatic hyperplasia.Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.Testosterone supplementation and body composition: results from a meta-analysis of observational studies.Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor.Testosterone Replacement Therapy: Long-Term Safety and Efficacy.Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?Ductal carcinoma of the prostate shows a different immunophenotype from high grade acinar cancer.Estrogens and Body Weight Regulation in Men.The safety of available treatments of male hypogonadism in organic and functional hypogonadism.Association between testosterone levels and the metabolic syndrome in adult men.Therapeutic implications of autophagy modulation in prostate cancerRisk and Benefit of Androgen Deprivation Therapy in Prostate CancerEffects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study
P2860
Q26864777-17831466-B882-4B9F-AAF7-CCFC9BC0DE7BQ28554489-0B9F9484-0B82-4BE4-B47E-5D181F0ADB2AQ33767832-F78EE7D2-0649-443B-A56A-A46580371BEBQ34332054-D4027026-7696-44C8-895D-2E6ED21AD100Q34449941-2C73C761-5FA3-4292-8EEE-36435D042FE2Q36287950-0C08A37D-6599-4441-8203-B5EBB7A8B785Q37137452-4A418AD6-2639-423F-94D2-401D0D1B7F5BQ37148238-159653F4-8BCF-43DC-88D6-B292AE11D0F5Q37165019-31AF42CB-14E3-4D9F-BD91-9F1AE05AE058Q37618958-89267553-0E2D-498C-8093-A47202EEA45EQ37686901-92519C4D-CF9C-4604-BDD2-8BB0036E8D15Q38088550-5C9EC0A7-26DC-4C10-81DC-4B4C2F007751Q38181426-3CD0B241-D97F-414F-99E3-D30E56411897Q38235669-63E13242-1A1D-4CBA-BCF7-D42A7A45977BQ38692706-C94F270C-AB5A-436F-9F82-CA7CEE210DB2Q38738470-6922BC6F-00A9-4123-A744-DC7E71D9AA9BQ38811041-B3D3C3B8-4E47-4FBD-9016-6D6BFB2308DBQ38814349-79BE8264-865C-4067-A0DB-84B862D9212BQ38848541-6AFA02DA-8BD2-4809-BFE3-256AA71A09D6Q39003600-7E67BBC3-6AA5-4BC0-94BB-B4AC7F10786FQ39192939-0DCF7C85-A8FB-4AF3-975D-A8C897FB6FF8Q39302080-7A867F2A-197E-428F-9487-4A25B4B569ABQ39870160-63E52097-1C2F-4A1F-9A88-923AC7780351Q41207124-8BB26F39-2A16-434B-9E6F-9146FFF9110CQ41548112-CF528D38-C5D2-4412-B081-BF70DCAA755AQ44747186-F34A82E9-5765-4EBC-870A-D0D12725D153Q47174327-6E43D353-0A00-461C-9ADE-67C0968F96EAQ50046284-F1EED13C-0B2B-4248-9030-BE6D2DA43F00Q50662671-395600C5-226F-48B5-9F44-111DE4DCB412Q57278844-444869F5-1BDB-43A2-847B-D6B5579AFBF2Q57582323-17B094BD-0AF4-46B9-918C-B03AD2CCBA83Q58279991-9BEF6075-5D8E-4588-8126-A125D3C021E8
P2860
Androgen regulation of prostate cancer: where are we now?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Androgen regulation of prostate cancer: where are we now?
@en
Androgen regulation of prostate cancer: where are we now?
@nl
type
label
Androgen regulation of prostate cancer: where are we now?
@en
Androgen regulation of prostate cancer: where are we now?
@nl
prefLabel
Androgen regulation of prostate cancer: where are we now?
@en
Androgen regulation of prostate cancer: where are we now?
@nl
P2093
P2860
P356
P1476
Androgen regulation of prostate cancer: where are we now?
@en
P2093
P2860
P2888
P304
P356
10.1007/BF03347072
P577
2011-02-04T00:00:00Z